Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.

ABSTRACT:

Background

Adoptive natural killer (NK) cell transfer is being increasingly used as cancer treatment. However, clinical responses have so far been limited to patients with hematological malignancies. A potential limiting factor in patients with solid tumors is defective homing of the infused NK cells to the tumor site. Chemokines regulate the migration of leukocytes expressing corresponding chemokine receptors. Various solid tumors, including renal cell carcinoma (RCC), readily secrete ligands for the chemokine receptor CXCR2. We hypothesize that infusion of NK cells expressing high levels of the CXCR2 chemokine receptor will result in increased influx of the transferred NK cells into tumors, and improved clinical outcome in patients with cancer.

Methods

Blood and tumor biop

SUBMITTER: Kremer V 

PROVIDER: S-EPMC5604543 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature